All stock lists
Aemetis, Inc (NASDAQ:AMTX)
US · Delayed Price · Currency is USD
Basic Materials · Chemicals - Specialty
1.81+0.56 (+44.91%)
Market cap
$131M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 27, 2006
Website
Insider Score
––Not scored
AMTX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Distressed
From AMTX’s reported statements · Q3 2026 (trailing 12 months)
Profitability4 / 20
Loses money on what it sells.
- Revenue
- $259.1M
- Net income
- -$31.2M
- Net margin
- -12.0%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $316.4M
- Cash
- $3.4M
- Net debt / EBITDA
- 29.87x
Liquidity0 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $29.1M
- Current liabilities
- $439.8M
- Current ratio
- 0.07
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- $15.3M
- Free cash flow
- -$36.6M
- FCF margin
- -14.1%
Dilution & runway9 / 20
Some dilution over the past year.
- Shares outstanding
- 72.5M
- Share growth (1y)
- 13.8%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
AMTX Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 88.15 M | 62.70 M | 54.62 M | 53.66 M | 59.19 M | 52.24 M |
| Revenue Growth (YoY) | 48.93 % | 20.02 % | 27.36 % | 14.16 % | -27.32 % | -21.51 % |
| Cost of Revenue | 58.68 M | 49.19 M | 51.86 M | 45.94 M | 59.25 M | 55.60 M |
| Gross Profit | 29.47 M | 13.52 M | 2.76 M | 7.72 M | -58.00 K | -3.35 M |
| SG&A Expense | 8.62 M | 7.74 M | 0.00 | 10.21 M | 8.45 M | 7.32 M |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.62 M | 7.74 M | 9.09 M | 10.21 M | 8.45 M | 7.32 M |
| Operating Income | 20.85 M | 5.77 M | -6.33 M | -2.48 M | -8.51 M | -10.67 M |
| Pretax Income | 5.21 M | -9.37 M | -21.84 M | -16.77 M | -23.74 M | -23.92 M |
| Tax Provision | 2.00 K | 0.00 | -131.00 K | -11.44 M | 6.00 K | -529.00 K |
| Net Income | 5.21 M | -9.37 M | -21.71 M | -5.33 M | -23.75 M | -23.39 M |
| EPS (Basic) | 0.07 | -0.13 | -0.33 | -0.08 | -0.37 | -0.41 |
| EPS (Diluted) | -0.02 | -0.13 | -0.33 | -0.08 | -0.37 | -0.41 |
| Shares Outstanding | 72.50 M | 70.89 M | 66.80 M | 65.78 M | 63.70 M | 57.68 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.